In multivariate analysis, trauma, renal failure, left-sided catheters, basilic placement, TPN, and infusion with antibiotics, specifically vancomycin, were significant risk factors for UEVT associated with PICC insertion. Prophylaxis with low molecular weight heparin, unfractionated heparin or use of warfarin did not prevent the development of venous thrombosis in patients with PICCs. Length of hospital stay and cost are markedly increased in patients who develop PICC-associated upper extremity venous thrombosis.
Dabbing" is the inhalation of concentrated marijuana, usually in butane solvent. This case report illustrates a previously healthy 25-year-old caucasian male with a 10-year history of cannabis butane hash oil (BHO) use. The patient presented with dyspnea and cough. The evaluation included a chest x-ray, basic laboratory investigations, computerized tomography angiogram of the chest and echocardiogram. Patient was diagnosed with acute lung injury mimicking atypical pneumonia. He was treated with steroids and had clinically improved and advised to stop dabbing. Further studies are needed to elucidate the full spectrum of the adverse effects of dabbing.
Objectives
HA is a natural component of the human body. It fulfills several biological functions including immune-modulation and anti-inflammatory effects. HA is considered to treat several andrological issues such as premature ejaculation, penile enlargement and recently Peyronie disease.
The aim of this study is to evaluate the safety and the efficacy of a new protocol based on intraplaque injection of cross-linked hyaluronic acid plus modeling and stretching, in men with the chronic phase of Peyronie's Disease.
Methods
At baseline all the patients were evaluated via intra-cavernous injection of a vasoactive agents and performed also the PD Questionnaire (PDQ) and the International Index of Erectile Function (IIEF) questionnaires.
The protocol consisted in an intraplaque injection of HA (under block of 15 mL plain mepivacain 1%) every other week for a total of three injections in six weeks, plus penile modeling after each injection. Each patient also performed a daily use of vacuum erection device and (self) modeling and stretching in the days following the injections.
Results
23 patients were recruited in the study. Two patients were excluded because they did not correctly performe home protocol. Median curvature at baseline was 55° (IQR= 45 - 65).
Nineteen out of 21 patients (90%) showed a reduction in the degree of curvature by a mean of 11.9 ± 7.3°. A statistically significant improvement in IIEF - Intercourse satisfaction domain (from baseline: 6.41 ± 3.8 to 8 week: 8.76 ± 2.8; p<0.001) and PDQ- Symptoms Bother domain (from baseline: 8.75 ± 4.1 to 8 week: 7.4 ± 3.3; p<0.001) was also detected.
Conclusions
The findings of the study show that this new protocol based is able to significantly reduce penile curvature in patients suffering from a chronic phase of PD.
Our intent is to continue the study further to better understand the impact that IIHA therapy on the management of PD in terms of patient satisfaction and reduction in the need for surgery.
Conflicts of Interest
The authors involved in this study certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.